Clinical significance of hepatocyte nuclear factor 4α in rectal cancer and its relationship with prognosis

Abstract

Abstract:ObjectiveTo investigate the clinical significance of hepatocyte nuclear factor 4α (HNF4α) in rectal cancer and its relationship with prognosis. MethodsRealtime PCR was designed to detect the expression of HNF4α on mRNA level and the immunohistochemistry was used to determine the expression of HNF4α on protein level in rectal cancer tissue. The relationship between HNF4α expression and clinical characteristics was also analysed. The KaplanMeier method was used for univariate analysis and a Cox proportional hazards regression model was performed for multivariate analysis. ResultsHNF4α was low expressed both on mRNA (t=6.092, P＜0.001) and protein level (χ2=15.230, P＜0.001) in rectal cancer tissue. HNF4α expression on protein level was related with the clinical stage (χ2=48.311, P＜0.001), depth of invasion (χ2=23.911, P＜0.001), histological differentiation (χ2=20.787, P＜0.001), lymph node metastasis (χ2=39.064, P＜0.001) and distant metastasis (χ2=5.146, P=0.04), while age and gender were not relevant. The cumulative 3year overall survival of patients with low HNF4α expression (43.8%) was much worse than the patients with high HNF4α expression (95.5%), and the difference was statistically significant (P＜0.001). Univariate analysis revealed that HNF4α expression (χ2=28.778, P＜0.001), differentiation (χ2=26.680, P＜0.001), clinical stage (χ2=32.702, P＜0.001), depth of invasion (χ2=6.226, P=0.013), lymph node invasion (χ2=15.270, P＜0.001) and distant metastasis (χ2=21.817, P＜0.001) were statistically significant worse predictors for rectal cancer, whereas age and gender were not relevant. The multivariate Cox proportional hazard analysis revealed that HNF4α low expression (RR=6.084, P=0.028) was independent prognostic markers for 3year overall survival in the patients with rectal cancer. ConclusionHNF4α was closely related to the tumorigenesis and progression of rectal cancer, which is an independent prognostic marker for rectal cancer, and which may be an effective target for the therapy of rectal cancer.

Key words:Rectal neoplasms,Immunohistochemistry,Hepatocyte nuclear factor 4α

Wang Juan, Ji Weiping, Yao Houshan, Wang Liangzhe, Hu Zhiqian. Clinical significance of hepatocyte nuclear factor 4α in rectal cancer and its relationship with prognosis[J]. Journal of International Oncology, 2014, 41(8): 704-708.

References

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 69-90. ［2］王浩, 陆培华, 陶国青, 等. 结直肠癌肝转移机制的研究进展［J］. 国际肿瘤学杂志, 2011, 38(9): 700-703. ［3］刘海义. 早期直肠癌的治疗进展［J］. 国际肿瘤学杂志, 2010, 37(9): 700-703. ［4］ Lazarevich NL, Shavochkina DA, Fleishman DI, et al. Deregulation of hepatocyte nuclear factor 4 (HNF4) as a marker of epithelial tumors progression［J］. Exp Oncol, 2010, 32(3): 167-171. ［5］ Oshima T, Kawasaki T, Ohashi R, et al. Downregulated P1 promoterdriven hepatocyte nuclear factor4alpha expression in human colorectal carcinoma is a new prognostic factor against liver metastasis［J］. Pathol Int, 2007, 57(2): 82-90. ［6］ Darsigny M, Babeu JP, Dupuis AA, et al. Loss of hepatocyte nuclear factor 4alpha affects colonic ion transport and causes chronic inflammation resembling inflammatory bowel disease in mice［J］. PLoS One, 2009, 4(10): e7609. ［7］ Takano K, Hasegawa G, Jiang S, et al. Immunohistochemical staining for P1 and P2 promoter driven hepatocyte nuclear factor4alpha may complement mucin phenotype of differentiatedtype early gastric carcinoma［J］. Pathol Int, 2009, 59(7): 462-470. ［8］ Yin C, Lin Y, Zhang X, et al. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor4alpha gene［J］. Hepatology, 2008, 48(5): 1528-1539. ［9］张梁, 元辉雄, 黄永秩, 等. 结直肠癌组织中HNF4α的细胞内定位及临床意义［J］. 检验医学, 2013, 28(3): 215-217. ［10］ Ehehalt F, Rümmele P, Kersting S, et al. Hepatocyte nuclear factor (HNF) 4α expression distinguishes ampullary cancer subtypes and prognosis after resection［J］. Ann Surg, 2011, 254(2): 302-310 ［11］ Chiba H, Itoh T, Satohisa S, et al. Activation of p21CIP1/WAF1 gene expression and inhibition of cell proliferation by overexpression of hepatocyte nuclear factor4alpha［J］. Exp Cell Res, 2005, 302(1): 11-21. ［12］ Yao D, Peng S, Dai C. The role of hepatocyte nuclear factor 4alpha in metastatic tumor formation of hepatocellular carcinoma and its close relationship with the mesenchymalepithelial transition markers［J］. BMC Cancer, 2013, 13: 432. ［13］ Ning BF, Ding J, Yin C, et al. Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma［J］. Cancer Res, 2010, 70(19): 7640-7651.

[1]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.
[6]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing.Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273.
[7]	Zeng Liwu, Du Yuqiang, Zhang Peng, Tao Kaixiong.Progress in imaging evaluation of lateral lymph node metastasis in rectal cancer[J]. Journal of International Oncology, 2023, 50(4): 248-251.
[8]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun.Construction of postoperative prognosis model for patients with colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 157-163.
[9]	Xu Liangfu, Li Yuanfei.Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 186-190.
[10]	Liao Lihua, Wang Shaohong, Chen Hongcai, Zhao Yongqiang.Value of cell paraffin block immunohistochemistry and pleural effusion CRKL and MIC-1 in the diagnosis of malignant pleural effusion[J]. Journal of International Oncology, 2023, 50(2): 71-75.
[11]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng.Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer[J]. Journal of International Oncology, 2023, 50(12): 717-722.
[12]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu.Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer[J]. Journal of International Oncology, 2023, 50(11): 683-687.
[13]	Wang Xi, Wu Chuanqing.Research progress in reversing multidrug resistance in colorectal cancer[J]. Journal of International Oncology, 2023, 50(1): 42-46.
[14]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang.Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer[J]. Journal of International Oncology, 2022, 49(9): 555-559.
[15]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang.Predictive value of inflammatory markers in colorectal cancer[J]. Journal of International Oncology, 2022, 49(9): 560-563.